The goal of this flexible approach is to identify patients most likely to benefit from appetite regulation and improved metabolic function
However, no human studies have examined truly long-term use extending over years or decades
So we think about the gutmetabolic axis here
Duke DC, Barry S, Wagner DV, Speight J, Choudhary P, Harris MA (2018) Distal technologies and type 1 diabetes management
For detailed clinical data from NEJM Falutz 2007 and Lancet HIV Stanley 2026, see our Tesamorelin science research guide
Trial Status: Recruiting Clinical Trials Identifier: NCT06797869 Trial Name: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Diabetes Type: Type 2 diabetes Trial Sponsor: Novo Nordisk A/S Why is this study important